Priority Date: 14.05.12 (US 201261646586P)

USING MODULATORS OF CCR5 FOR TREATING CANCER

  • Application ID: EP13790117
  • Status: GRANT OF PATENT INTENDED

Attorneys

operating since 1887
1384.64
Headquarter in London and 20 offices
active in Legal Services, IP Consulting, and Matchmaking and Trading
operating since 1887
1384.64
Headquarter in London and 20 offices
active in Legal Services, IP Consulting, and Matchmaking and Trading

Specialization

This EP application has the IPC class A61, C12, and G01. We found, that TransMIT GmbH, Kailuweit & Uhlemann, dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB, Avidity IP Ltd, Mewburn Ellis LLP and 74 others are specialized in this combination either. For a similar patent, they might be a good choice.

Timeline

  • 14.05.2012 - Priority Date (US 201261646586P)
  • 21.11.2013 - Publication A1 (WO2013173312)
  • 22.04.2015 - Publication A1 (EP2861302)

IPC Classification